Charles Schwab’s Cardlytics CDLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-26,972
| Closed | -$444K | – | 3475 |
|
|
2025
Q2 | $444K | Sell |
26,972
-7,097
| -21% | -$123K | ﹤0.01% | 3176 |
|
|
2025
Q1 | $620K | Sell |
34,069
-6,186
| -15% | -$177K | ﹤0.01% | 3002 |
|
|
2024
Q4 | $1.49M | Buy |
40,255
+1,221
| +3% | +$46.7K | ﹤0.01% | 2771 |
|
|
2024
Q3 | $1.25M | Buy |
39,034
+1,138
| +3% | +$63.2K | ﹤0.01% | 2855 |
|
|
2024
Q2 | $3.11M | Buy |
37,896
+6,184
| +20% | +$669K | ﹤0.01% | 2549 |
|
|
2024
Q1 | $4.6M | Buy |
31,712
+277
| +0.9% | +$23.4K | ﹤0.01% | 2320 |
|
|
2023
Q4 | $2.9M | Buy |
31,435
+3,126
| +11% | +$318K | ﹤0.01% | 2511 |
|
|
2023
Q3 | $4.67M | Buy |
28,309
+3,223
| +13% | +$419K | ﹤0.01% | 2292 |
|
|
2023
Q2 | $1.59M | Buy |
25,086
+680
| +3% | +$41.2K | ﹤0.01% | 2625 |
|
|
2023
Q1 | $829K | Buy |
24,406
+3,456
| +16% | +$181K | ﹤0.01% | 2802 |
|
|
2022
Q4 | $1.21M | Sell |
20,950
-2,772
| -12% | -$171K | ﹤0.01% | 2719 |
|
|
2022
Q3 | $2.23M | Sell |
23,722
-310
| -1% | -$44.1K | ﹤0.01% | 2554 |
|
|
2022
Q2 | $5.36M | Buy |
24,032
+83
| +0.3% | +$27.8K | ﹤0.01% | 2160 |
|
|
2022
Q1 | $13.2M | Buy |
23,949
+629
| +3% | +$380K | ﹤0.01% | 1799 |
|
|
2021
Q4 | $15.4M | Buy |
23,320
+570
| +3% | +$436K | ﹤0.01% | 1762 |
|
|
2021
Q3 | $19.1M | Buy |
22,750
+225
| +1% | +$228K | 0.01% | 1630 |
|
|
2021
Q2 | $28.6M | Buy |
22,525
+1,507
| +7% | +$1.7M | 0.01% | 1288 |
|
|
2021
Q1 | $23.1M | Buy |
21,018
+3,138
| +18% | +$4.14M | 0.01% | 1408 |
|
|
2020
Q4 | $25.5M | Buy |
17,880
+296
| +2% | +$316K | 0.01% | 1219 |
|
|
2020
Q3 | $12.4M | Buy |
17,584
+2,657
| +18% | +$1.93M | 0.01% | 1537 |
|
|
2020
Q2 | $10.4M | Buy |
14,927
+3,704
| +33% | +$2.14M | 0.01% | 1622 |
|
|
2020
Q1 | $3.92M | Buy |
11,223
+218
| +2% | +$154K | ﹤0.01% | 1946 |
|
|
2019
Q4 | $6.92M | Buy |
11,005
+1,056
| +11% | +$516K | ﹤0.01% | 1853 |
|
|
2019
Q3 | $3.34M | Buy |
9,949
+6,528
| +191% | +$2.09M | ﹤0.01% | 2175 |
|
|
2019
Q2 | $889K | Buy |
3,421
+2,034
| +147% | +$407K | ﹤0.01% | 2616 |
|
|
2019
Q1 | $230K | Hold |
1,387
| – | – | ﹤0.01% | 2997 |
|
|
2018
Q4 | $151K | Hold |
1,387
| – | – | ﹤0.01% | 3051 |
|
|
2018
Q3 | $348K | Buy |
1,387
+407
| +42% | +$87.6K | ﹤0.01% | 2960 |
|
|
2018
Q2 | $214K | Buy |
+980
| New | +$181K | ﹤0.01% | 3055 |
|
Other funds holding CDLX
6CM
Charles Schwab's CDLX Position: Q3 2025 in Review
Charles Schwab sold out of Cardlytics (CDLX) in Q3 2025, closing a stake of 26,972 shares — an estimated $444K sold.
Charles Schwab first reported a position in CDLX in Q2 2018 and held it in 29 quarters. The position peaked at $28.6M in Q2 2021. 81 funds tracked by Wall St. Rank hold CDLX as of Q3 2025.
- Charles Schwab reported no remaining Cardlytics position as of Q3 2025 after selling out during the quarter.
- Charles Schwab sold 26,972 Cardlytics shares in Q3 2025, an estimated $444K.
- Charles Schwab first reported a position in Cardlytics in Q2 2018 and held it in 29 quarters.
- Charles Schwab's Cardlytics position peaked at $28.6M in Q2 2021.
- 81 funds tracked by Wall St. Rank held Cardlytics as of Q3 2025.
Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.